Balovaptan

Clinical data
Other names	RG7314
Legal status
Legal status	US: ℞-only
Identifiers
IUPAC name 8-Chloro-5-methyl-1-(4-pyridin-2-yloxycyclohexyl)-4,6-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
CAS Number	1228088-30-9
PubChem CID	46200932
DrugBank	DB14823
ChemSpider	59718648
UNII	RAX5D5AGV6
KEGG	D11476
Chemical and physical data
Formula	C22H24ClN5O
Molar mass	409.92 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN1CC2=NN=C([C@H]3CC[C@@H](CC3)OC3=CC=CC=N3)N2C2=C(C1)C=C(Cl)C=C2
InChI InChI=1S/C22H24ClN5O/c1-27-13-16-12-17(23)7-10-19(16)28-20(14-27)25-26-22(28)15-5-8-18(9-6-15)29-21-4-2-3-11-24-21/h2-4,7,10-12,15,18H,5-6,8-9,13-14H2,1H3/t15-,18- Key:GMPZPHGHNDMRKL-RZDIXWSQSA-N

Balovaptan (INNTooltip International Nonproprietary Name; developmental code name RG7314), is a selective small molecule antagonist of the vasopressin V_1A receptor which is under development by Roche for the treatment of post-traumatic stress disorder.^[1] It was in a phase III clinical trial for adults and a phase II clinical trial for children for this indication.^[2] On 29 January 2018, Roche announced that the US Food and Drug Administration (FDA) had granted Breakthrough Therapy Designation for balovaptan in individuals with autism spectrum disorder (ASD).^[3] The FDA granted this based on the results of the adult phase II clinical trial called VANILLA (Vasopressin ANtagonist to Improve sociaL communication in Autism) study.^[4] The phase III adult study (March 2020) is called V1aduct and the currently-closed (August 2019) phase II child study is called Av1ation.^{[citation needed]} It was also in phase II studies for the treatment of stroke. However, it has since been discontinued for both of those indications, and is only being developed for post-traumatic stress disorder, with plans to submit regulatory filings in 2025 or later.^[5]